News - ExCellThera

August 27, 2025

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells

Zemcelpro® is conditionally authorized by the European Commission for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available Zemcelpro® will increase access to allogeneic stem cell transplantation to treat life-threatening haematologic malignancies, including leukemias and myelodysplastic syndromes Timing of […]

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

– If approved, Zemcelpro® is expected to: increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromes be the first and only therapy in the European Union with marketing authorization for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative […]

ExCellThera announces new UM171 presentation on advances in stem cell transplant at the EBMT Annual Meeting

Dr. Guy Sauvageau, Chief Scientific Officer at ExCellThera will present on improving stem cell quality with UM171 for better transplant outcome MONTREAL, March 25, 2025 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today that Dr. Guy Sauvageau, the company’s Chief Scientific Officer, will present on significant […]